Arrowstreet Capital Limited Partnership Boosts Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Arrowstreet Capital Limited Partnership increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 409.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,956 shares of the medical research company's stock after purchasing an additional 29,707 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 0.13% of Bio-Rad Laboratories worth $12,140,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of BIO. Wealthfront Advisers LLC bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth $342,686,000. Norges Bank acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at $41,644,000. Wedge Capital Management L L P NC acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at $28,740,000. Proficio Capital Partners LLC acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at $9,820,000. Finally, DAVENPORT & Co LLC lifted its holdings in Bio-Rad Laboratories by 48.8% in the fourth quarter. DAVENPORT & Co LLC now owns 84,677 shares of the medical research company's stock valued at $27,817,000 after buying an additional 27,780 shares during the period. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Down 6.5 %

NYSE:BIO traded down $16.10 during mid-day trading on Thursday, hitting $233.07. 56,403 shares of the company's stock were exchanged, compared to its average volume of 312,818. The business has a fifty day moving average price of $269.27 and a 200 day moving average price of $315.95. The company has a market cap of $6.53 billion, a PE ratio of -3.58 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a one year low of $215.38 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BIO shares. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.